Clinical trials: Inflammatory Disease
Inflammatory Bowel Disease (IBD), Crohn's Disease
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland
The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
- Trial name
- VARIETY (NCT05384080)
- Where
- 11 sites in Poland
- Volunteers
- 165 people
- Sponsor
- Takeda
Healthy Adult Volunteers, Active Ulcerative Colitis
A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
This Phase 1b/2a clinical development plan is focused on the use of NP-201 acetate injection to investigate the pharmacokinetics (PK), safety, efficacy, PD (pharmacodynamic) markers (Phase 1b) and tolerability of NP-201 acetate…
- Conditions
- Healthy Adult Volunteers, Active Ulcerative Colitis, Active Ulcerative Colitis (UC)
- Trial name
- NCT06681389
- Testing
- NP-201 acetate injection (Part A)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- NIBEC Co., Ltd.
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Colitis, Ulcerative
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active…
- Trial name
- NCT03482635
- Testing
- Spesolimab
- Where
- 54 sites in United States, Austria and 10 more
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Polymyalgia Rheumatica, Inflammatory Diseases
A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica
The study is a two-week, single-blinded, double-dummy, randomized, active-controlled, parallel group design, with a follow-up period up to a total study duration of 6-month, non-randomized, open-label phase to monitor safety…
- Trial name
- NCT01364389
- Testing
- AIN457, ACZ885, Prednisone
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Inflammation, Interleukin-1beta
Effect on Cytokines IL-1ß, TNF-α, IL-4, and Total Bacterial Load of a Composition Comprising Olive Oil, Trimethylglycine and Xylitol Delivered as a Toothpaste
The goal of this clinical trial is to learn if a novel composition comprising olive oil, trimethylglycine and xylitol, affects salivary levels of IL-1ß, TNF-α and IL-4 in a group of periodontally healthy, normal and…
- Conditions
- Inflammation, Interleukin-1beta, TNF-α, Cytokine Levels
- Trial name
- NCT06786910
- Testing
- Toothpaste with olive oil, trimethylglycine and xylitol, Toothpaste without olive oil, trimethylglycine nor xylitol
- Where
- Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mucosa Innovations, S.L.
Ulcerative Colitis, Crohn's Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase…
- Trial name
- NCT03650413
- Testing
- UTTR1147A
- Where
- 57 sites in United States, Bulgaria and 12 more
- Volunteers
- 143 people
- Sponsor
- Genentech, Inc.
Coronary Artery Disease, Acute Myocardial Infarction (AMI)
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized…
- Conditions
- Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery
- Trial name
- ZEPHYR (NCT07276282)
- Testing
- Ziltivekimab
- Where
- Switzerland
- Volunteers
- 332 people
- Sponsor
- ECRI bv
Ulcerative Colitis
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. Participants with UC have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon.
- Trial name
- PROFUNDUS (NCT05494606)
- Where
- 153 sites in Argentina, Australia and 15 more
- Volunteers
- 785 people
- Sponsor
- AbbVie
Ulcerative Colitis
Efficacy and Safety of Oral BT-11 in Ulcerative Colitis
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter study with an optional open-label extension (OLE) period.
- Trial name
- NCT03861143
- Testing
- BT-11 (440 mg), BT-11 (880 mg)
- Where
- 16 sites in United States, Bosnia and Herzegovina and 3 more
- Volunteers
- 198 people
- Sponsor
- NImmune Biopharma
Ulcerative Colitis
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a…
- Trial name
- NCT01805791
- Testing
- HMPL-004 1800 mg/day, HMPL-004 2400 mg/day
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Hutchison Medipharma Limited
Hyperpigmentation
Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins
The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to…
- Trial name
- NCT06320314
- Testing
- tested product (2039125 03)
- Where
- Portugal
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Rheumatoid Arthritis
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of…
- Trial name
- NCT00147498
- Testing
- CP-690,550
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 264 people
- Sponsor
- Pfizer
Crohn´s Disease
A Study With Pentasa in Patients With Active Crohn's Disease
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
- Trial name
- PEACE (NCT00862121)
- Testing
- Pentasa
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
- Trial name
- NCT03281304
- Testing
- CP-690,500 5 mg, CP-690,550 10 mg
- Where
- 80 sites in United States, Belgium and 18 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Crohn's Disease
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] due to an exacerbation of Crohn's Disease.
- Trial name
- PRECiSE 4 (NCT00160706)
- Testing
- Certolizumab Pegol (CDP870)
- Where
- 141 sites in United States, Australia and 22 more
- Volunteers
- 310 people
- Sponsor
- UCB Pharma SA
Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
- Trial name
- NCT02536404
- Testing
- Etrasimod
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 118 people
- Sponsor
- Arena Pharmaceuticals
Crohn's Disease
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
- Trial name
- NCT00078611
- Testing
- natalizumab
- Where
- 75 sites in United States, Canada
- Volunteers
- 462 people
- Sponsor
- Biogen
Ulcerative Colitis
Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a…
- Trial name
- NCT00209287
- Testing
- Observe patients with inactive ulcerative colitis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease.
- Trial name
- NCT02974322
- Testing
- GED-0301
- Where
- 311 sites in United States, Australia and 28 more
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.